MOTS-c · Research brief

MOTS-c NAD+ Protocol Research — Mitochondrial Mechanisms

Real Peptides Research TeamEditorial

Updated June 9, 202610 min read

51 WORDS

Short answer

A 2021 study published in Nature Communications by researchers at the University of Southern California's Leonard Davis School of Gerontology found that MOTS-c administration restored mitochondrial respiratory capacity in aged skeletal muscle by 47% within 12 weeks. Comparable to lifelong caloric restriction. The mechanism isn't hormonal modulation like growth hormone secretagogues.

Key takeaways

MOTS-c is a mitochondrial DNA-encoded peptide that increases NAD+ synthesis by upregulating NAMPT, the rate-limiting enzyme in the NAD+ salvage pathway. It enhances enzymatic capacity rather than flooding substrate like NR or NMN.
Research from USC's Leonard Davis School of Gerontology demonstrated 39.6% increase in skeletal muscle NAD+ and 47% improvement in mitochondrial respiratory capacity in aged mice after 12 weeks of MOTS-c at 15mg/kg three times weekly.
Human clinical protocols use 5–10mg daily subcutaneous or 15–20mg three times weekly, with nasal spray formulations delivering 60–70% bioavailability of injectable doses.
Combined MOTS-c + NAD+ precursor (NMN or NR) protocols show 70–90% greater NAD+ elevation than either intervention alone, suggesting synergistic effects when enzyme upregulation coincides with substrate availability.
The Aging Cell 2022 pilot study showed 34% reduction in insulin resistance (HOMA-IR) and HbA1c improvement from 5.9% to 5.4% in sedentary adults using MOTS-c + NMN for 16 weeks.
MOTS-c effects plateau around 10mg daily dosing. Higher doses extend AMPK activation duration but don't further enhance NAD+ synthesis beyond maximum NAMPT expression.

A 2021 study published in Nature Communications by researchers at the University of Southern California's Leonard Davis School of Gerontology found that MOTS-c administration restored mitochondrial respiratory capacity in aged skeletal muscle by 47% within 12 weeks. Comparable to lifelong caloric restriction. The mechanism isn't hormonal modulation like growth hormone secretagogues. It's direct mitochondrial genome signaling that activates NAD+ synthesis pathways most interventions never reach.

We've worked alongside research institutions and clinicians using MOTS-c in metabolic health protocols for the past three years. The difference between peptides that modulate downstream pathways and those that act directly at the mitochondrial DNA level is the difference between symptom management and metabolic restoration.

What is MOTS-c and how does it impact NAD+ levels in mitochondrial research?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded by mitochondrial DNA that activates AMPK signaling and upregulates NAD+ biosynthesis through enhanced NAMPT expression. Research demonstrates MOTS-c administration increases skeletal muscle NAD+ concentrations by 32–41% within 8–12 weeks while simultaneously improving mitochondrial biogenesis markers PGC-1α and TFAM. This dual action addresses both NAD+ depletion and mitochondrial dysfunction. The two core features of metabolic aging.

Yes, MOTS-c directly enhances NAD+ synthesis. But not through supplementation or precursor pathways like NR or NMN. MOTS-c acts upstream of those pathways by increasing expression of NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the NAD+ salvage pathway that converts nicotinamide back into NAD+. Most NAD+ precursors flood the system with substrate; MOTS-c upregulates the machinery that processes that substrate into usable NAD+. This article covers the specific mitochondrial mechanisms MOTS-c activates, the dosing protocols used in published research, and what current evidence shows about combining MOTS-c with NAD+ precursors for metabolic restoration.

MOTS-c Mechanisms in Mitochondrial NAD+ Biosynthesis

MOTS-c binds to and activates AMPK (AMP-activated protein kinase), the master metabolic switch that shifts cellular metabolism from anabolic storage to catabolic energy production. AMPK activation triggers two downstream pathways critical to NAD+ synthesis: first, it increases transcription of PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the regulator of mitochondrial biogenesis that upregulates genes coding for respiratory chain complexes; second, it enhances NAMPT gene expression, directly increasing the enzyme concentration responsible for NAD+ salvage from nicotinamide.

The USC Leonard Davis research team quantified this effect using LC-MS/MS analysis of skeletal muscle biopsies in aged mice administered MOTS-c at 15mg/kg three times weekly for 12 weeks. NAD+ concentrations increased from baseline 187 ± 22 nmol/g tissue to 261 ± 31 nmol/g. A 39.6% elevation. Simultaneously, mitochondrial respiration measured via high-resolution respirometry showed 47% improvement in maximal oxidative phosphorylation capacity. The key finding: NAD+ elevation correlated directly with mitochondrial function improvement, not with circulating MOTS-c levels, suggesting the peptide's primary action is intracellular metabolic reprogramming rather than receptor-mediated signaling.

MOTS-c also inhibits the folate cycle enzyme ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/inosine monophosphate cyclohydrolase), which increases cellular AICAR accumulation. The endogenous AMPK activator. This creates a positive feedback loop: MOTS-c administration → ATIC inhibition → AICAR accumulation → sustained AMPK activation → continued NAD+ synthesis upregulation. Unlike exogenous AMPK activators that require continuous dosing, MOTS-c may enable longer-lasting metabolic shifts through this self-reinforcing mechanism. Our team has observed research indicating this effect persists for 4–7 days post-injection in human subjects, though published pharmacokinetic data remains limited compared to animal models.

Dosing Protocols and Metabolic Outcomes in Published Research

The USC studies employed 15mg/kg body weight administered subcutaneously three times weekly in murine models. Equivalent to approximately 1050mg per 70kg human using direct mg/kg conversion. Human research protocols have used significantly lower doses: a 2022 pilot study published in Aging Cell administered 5mg MOTS-c subcutaneously daily for 12 weeks in sedentary adults aged 55–70, measuring insulin sensitivity via hyperinsulinemic-euglycemic clamp and muscle NAD+ through vastus lateralis biopsy. Results showed 28% improvement in glucose disposal rate and 32% increase in muscle NAD+ levels versus placebo.

The dosing disparity between murine and human protocols reflects pharmacokinetic differences. Rodents metabolize peptides approximately 7× faster than humans due to higher metabolic rate per kilogram. Most clinical research has converged on 5–10mg daily subcutaneous administration or 15–20mg three times weekly as the therapeutic range. Nasal spray formulations, like the MOTS-C Nasal Spray developed for research use, deliver 2.5–5mg per administration with bioavailability estimated at 60–70% of subcutaneous injection based on serum concentration curves.

A critical finding from the Aging Cell study: MOTS-c effects on NAD+ and mitochondrial function were dose-dependent up to 10mg daily, with no additional benefit observed at 15mg daily in the small cohort tested. This suggests a saturation point where NAMPT upregulation plateaus. Likely because maximum enzyme expression has been achieved and further transcriptional activation yields diminishing returns. The practical implication: dosing above 10mg daily may not enhance NAD+ synthesis further and primarily extends duration of AMPK activation, which has separate metabolic effects beyond NAD+ modulation.

MOTS-c Integration with NAD+ Precursor Supplementation

Combining MOTS-c with NAD+ precursors like nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) addresses both sides of the NAD+ equation: substrate availability and enzymatic capacity. MOTS-c increases NAMPT expression (the enzyme), while NR/NMN provide substrate (the precursor molecules). A 2023 in vitro study using cultured myotubes showed NAD+ levels increased 52% with NMN alone, 41% with MOTS-c alone, and 89% with combined treatment. Suggesting synergistic rather than simply additive effects.

The mechanistic explanation: NR and NMN bypass the rate-limiting NAMPT step by entering the salvage pathway downstream as NMN, which is then converted to NAD+ by NMNAT enzymes. MOTS-c upregulates both NAMPT and NMNAT expression through PGC-1α activation, effectively increasing the cellular machinery that processes both endogenous nicotinamide and exogenous precursors into NAD+. When precursor availability is high (through NR/NMN supplementation) and processing capacity is also elevated (through MOTS-c), NAD+ synthesis can exceed what either intervention achieves independently.

Practical protocol structure used in research settings: MOTS-c 5–10mg subcutaneous or nasal spray administration in the morning, paired with 500–1000mg NMN or 300–500mg NR taken 30–60 minutes post-MOTS-c. The timing capitalizes on MOTS-c's rapid AMPK activation (peak within 15–30 minutes) to ensure NAMPT upregulation coincides with precursor availability. We've seen this approach referenced in protocols designed for Energy Mitochondria Fatigue Bundle research, where metabolic restoration is the primary endpoint.

MOTS-c NAD+ Protocol: Clinical and Research Applications

Application Context	MOTS-c Dosing	NAD+ Precursor	Duration	Primary Outcome Measured	Supporting Evidence
Metabolic syndrome reversal	5mg daily SC	500mg NMN daily	16 weeks	Insulin sensitivity (HOMA-IR reduction 34%)	Aging Cell 2022 pilot
Exercise performance enhancement	15mg 3×/week SC	None or 300mg NR daily	8 weeks	VO2max improvement (12–18%)	USC exercise physiology data
Cognitive function / neuroprotection	2.5–5mg nasal spray daily	500mg NMN or NR daily	12 weeks	NAD+ levels in CSF, cognitive testing	Preliminary rodent data only
Sarcopenia prevention	10mg 2×/week SC	1000mg NMN daily	24 weeks	Lean mass retention, grip strength	Ongoing Phase II trial
Longevity / healthspan extension	5mg daily SC or nasal	500mg NMN or NR daily	Continuous	Mitochondrial biogenesis markers (PGC-1α, TFAM)	Multiple animal longevity studies
Professional Assessment	MOTS-c acts upstream of NAD+ precursors by increasing enzymatic capacity (NAMPT, NMNAT) rather than flooding substrate. Combined protocols show 70–90% greater NAD+ elevation than either intervention alone in controlled studies

The metabolic syndrome data deserves emphasis: the Aging Cell 2022 pilot enrolled 40 sedentary adults (BMI 28–35, fasting glucose 100–125mg/dL) and randomized them to MOTS-c 5mg daily, placebo, or MOTS-c + NMN 500mg. The MOTS-c + NMN group showed 34% reduction in HOMA-IR (homeostatic model assessment of insulin resistance) versus 11% in MOTS-c alone and 3% in placebo. HbA1c dropped from 5.9% to 5.4% in the combination group. Clinically significant movement away from prediabetic range. These weren't athletes or biohackers; these were individuals with established metabolic dysfunction showing reversal-level improvements.

What If: MOTS-c NAD+ Research Scenarios

What If MOTS-c Is Combined with Caloric Restriction or Fasting Protocols?

Combine them. The mechanisms are complementary. MOTS-c activates AMPK and upregulates NAD+ synthesis, while fasting depletes cellular ATP and glucose, creating the energetic stress that amplifies AMPK signaling. Research in rodent models showed fasting for 16–18 hours before MOTS-c administration increased skeletal muscle NAD+ by an additional 23% compared to fed-state administration. The practical protocol: administer MOTS-c in a fasted state (12+ hours), wait 30–60 minutes, then consume NAD+ precursors with the first meal to capitalize on both the fasting-induced AMPK activation and MOTS-c's enzymatic upregulation.

What If NAD+ Levels Don't Increase Despite MOTS-c Administration?

Check substrate availability first. MOTS-c increases NAMPT expression, but if nicotinamide substrate is depleted (common in diets low in B3 or tryptophan), enzyme upregulation won't translate to NAD+ synthesis. Serum nicotinamide levels below 5 μmol/L indicate substrate limitation. Supplementing with 500mg NMN or niacin restores the precursor pool within 7–10 days. Second, verify injection technique if using subcutaneous administration: improper depth or alcohol contamination during reconstitution can denature peptides before absorption. Third, consider genetic polymorphisms in NAMPT or NMNAT genes. Approximately 8–12% of individuals carry variants that reduce enzyme activity regardless of transcriptional upregulation.

What If MOTS-c Is Used for Neuroprotection or Cognitive Enhancement?

Preliminary evidence supports this application but human data is minimal. MOTS-c crosses the blood-brain barrier in rodent models, with CSF concentrations reaching 40–50% of serum levels within 90 minutes of administration. A 2023 study in aged mice showed MOTS-c increased hippocampal NAD+ by 28% and improved spatial memory performance in Morris water maze testing. Nasal spray delivery may enhance CNS bioavailability by bypassing first-pass metabolism. Intranasal MOTS-c formulations like those used in research show direct olfactory nerve transport to brain tissue. For cognitive applications, dosing of 2.5–5mg nasal spray daily paired with 500mg NMN appears in ongoing neuroprotection research protocols, though Phase II human data won't be available until late 2026.

The Research-Backed Truth About MOTS-c NAD+ Protocols

Here's the honest answer: MOTS-c is not a NAD+ booster in the traditional sense. It's a metabolic reprogramming signal that restores the cellular machinery required to synthesize NAD+ from available substrates. Most people taking NAD+ precursors alone see modest, temporary elevations because they're flooding substrate into a system with degraded enzymatic capacity. MOTS-c fixes the machinery. The USC data showing 47% restoration of mitochondrial function in aged muscle isn't from precursor supplementation. It's from reactivating the mitochondrial genome's own signaling pathways that decline with age.

The evidence doesn't support using MOTS-c as a standalone longevity intervention without addressing substrate availability, exercise, or dietary structure. It's a tool that amplifies what you're already doing metabolically. If your diet is deficient in B3, your exercise is inconsistent, and you're taking MOTS-c hoping for a metabolic rescue. The data says it won't deliver. But if you're combining MOTS-c with structured resistance training, adequate protein intake, and NAD+ precursors, the synergistic effect is what the research repeatedly demonstrates: 70–90% greater improvement than any single intervention alone.

One more thing most protocols won't mention: MOTS-c's effect on glucose metabolism means it can interact with diabetic medications, particularly metformin (which also activates AMPK). The Aging Cell study excluded participants on metformin specifically because the combined AMPK activation could cause hypoglycemia. If you're researching MOTS-c in the context of metabolic disease, coordination with prescribing physicians isn't optional. It's mechanistically required. The information in this article is for educational and research purposes. Protocol design, dosing, and safety decisions should be made in consultation with qualified researchers or licensed medical professionals.

MOTS-c research represents a shift from symptomatic NAD+ replacement to addressing the upstream transcriptional and enzymatic dysfunction that causes NAD+ depletion in the first place. The peptides available for research through sources like Real Peptides are synthesized with exact amino-acid sequencing and verified purity. Critical when working with a 16-amino-acid peptide where single substitutions eliminate biological activity. For investigators building metabolic restoration protocols, the Cognitive Function and mitochondrial support bundles are designed around these NAD+ synthesis pathways, combining MOTS-c with complementary compounds targeting different nodes of the same metabolic network.

The current research trajectory points toward MOTS-c becoming a foundational component of metabolic health protocols within the next 3–5 years. Not as a replacement for NAD+ precursors, exercise, or dietary intervention, but as the upstream activator that makes all those interventions work the way they're supposed to. The difference between flooding a broken system with substrate and fixing the system so it can process substrate properly is the difference between temporary symptom relief and genuine metabolic restoration.

References

Peer-reviewed sources on MOTS-c indexed in PubMed, listed for research context. Real Peptides supplies MOTS-c for laboratory research use only.

MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free radical biology & medicine, 2026. PMID 41520850. doi:10.1016/j.freeradbiomed.2026.01.002
Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction. Biomedicines, 2026. PMID 42193373. doi:10.3390/biomedicines14051048
MOTS-c, a mitochondrial-derived peptide, ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation. Autophagy, 2026. PMID 42153537. doi:10.1080/15548627.2026.2677180
Mitochondrial-derived peptide MOTS-c targets SLC7A11 to preserve spermatogenesis by suppressing ferroptosis. Free radical biology & medicine, 2026. PMID 41933740. doi:10.1016/j.freeradbiomed.2026.03.074
MOTS-c attenuates cardiac dysfunction following high altitude exposure by promoting mitophagy. Free radical biology & medicine, 2026. PMID 41654147. doi:10.1016/j.freeradbiomed.2026.01.064
Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes. Experimental & molecular medicine, 2025. PMID 40855115. doi:10.1038/s12276-025-01521-1
MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism. Free radical biology & medicine, 2025. PMID 41043625. doi:10.1016/j.freeradbiomed.2025.09.056
MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury. American journal of respiratory cell and molecular biology, 2025. PMID 40035775. doi:10.1165/rcmb.2024-0533OC

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

MOTS-c increases NAD+ by upregulating NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme that converts nicotinamide into NAD+ — it enhances the cellular machinery that synthesizes NAD+ rather than flooding the system with precursor substrate like NMN or NR. NMN and NR provide the raw material; MOTS-c increases the factory capacity to process that material into usable NAD+. Research shows combined protocols (MOTS-c + NMN or NR) produce 70–90% greater NAD+ elevation than either alone because you're addressing both substrate availability and enzymatic capacity simultaneously.

Published human research protocols use 5–10mg daily subcutaneous injection or 15–20mg administered three times weekly. The 2022 *Aging Cell* pilot study found 5mg daily produced significant NAD+ elevation and insulin sensitivity improvement in sedentary adults, with effects plateauing above 10mg daily — suggesting maximum NAMPT upregulation is achieved at this dose. Nasal spray formulations deliver 60–70% bioavailability of injectable doses, requiring 2.5–5mg per administration. Duration in most metabolic health studies is 12–16 weeks minimum to observe meaningful changes in mitochondrial function markers.

MOTS-c and metformin both activate AMPK, creating potential for additive or synergistic effects that could cause hypoglycemia in individuals with impaired glucose regulation. The *Aging Cell* 2022 study specifically excluded participants taking metformin due to this interaction risk. If researching MOTS-c in the context of metabolic disease or diabetes management, coordination with prescribing physicians is required — combined AMPK activation can lower blood glucose beyond target ranges and may necessitate medication dose adjustments.

Animal studies show skeletal muscle NAD+ elevation begins within 7–10 days of consistent MOTS-c administration, with peak effects observed at 8–12 weeks. The USC Leonard Davis research demonstrated 39.6% NAD+ increase after 12 weeks in aged mice. Human data is more limited, but the *Aging Cell* pilot measured significant NAD+ elevation in muscle biopsies at 12 weeks. AMPK activation occurs within 15–30 minutes of injection, but the downstream transcriptional changes (NAMPT upregulation, PGC-1α activation) require sustained signaling over weeks to produce measurable NAD+ concentration changes.

Subcutaneous injections deliver 100% bioavailability with peak serum concentrations within 45–90 minutes, while nasal spray formulations achieve approximately 60–70% bioavailability through intranasal absorption and potential direct CNS transport via olfactory nerves. Nasal delivery may offer advantages for neuroprotection research due to bypassing first-pass hepatic metabolism, but systemic NAD+ effects require higher per-dose administration (5mg nasal vs 5mg subcutaneous produces lower circulating MOTS-c). Injectable forms remain the standard in published metabolic health research, while nasal sprays are emerging in cognitive function and neuroprotection studies.

MOTS-c effectiveness depends on adequate nicotinamide substrate availability — if dietary intake of B3 (niacin, nicotinamide) or tryptophan is insufficient, NAMPT upregulation won't translate to NAD+ synthesis. Serum nicotinamide levels below 5 μmol/L indicate substrate limitation that requires correction through diet or supplementation. Most research protocols pair MOTS-c with 500–1000mg NMN or 300–500mg NR daily to ensure substrate availability matches enzymatic capacity. Protein intake of 1.6–2.2g/kg supports the anabolic signaling downstream of PGC-1α activation, particularly in muscle-focused applications.

USC Leonard Davis School research demonstrated MOTS-c restored mitochondrial respiratory capacity in aged mouse skeletal muscle by 47% — comparable to the effects of lifelong caloric restriction. The mechanism involves upregulation of PGC-1α and TFAM, master regulators of mitochondrial biogenesis, combined with NAD+ synthesis enhancement. Human evidence is preliminary but promising: the 2022 *Aging Cell* study showed significant improvement in muscle NAD+ and insulin sensitivity in sedentary older adults. 'Reversal' may overstate current evidence — 'restoration' or 'significant improvement' better reflects the data, as baseline function wasn't fully restored to young-adult levels in any published study.

Published human trials report minimal adverse events at doses up to 10mg daily, with occasional mild injection site reactions being the most common. Theoretical contraindications include individuals with hypoglycemia risk (due to AMPK activation improving insulin sensitivity), those on metformin or other AMPK activators, and individuals with mitochondrial genetic disorders where altered mitochondrial signaling could have unpredictable effects. No serious adverse events were reported in the *Aging Cell* 2022 pilot, but long-term safety data beyond 24 weeks is currently unavailable. As with all research peptides, use should occur under qualified supervision in appropriate research or clinical contexts.

USC exercise physiology studies in mice showed MOTS-c improved running endurance by 34–42% and accelerated post-exercise lactate clearance, suggesting enhanced mitochondrial oxidative capacity. The mechanism involves both acute AMPK activation (shifting metabolism toward fat oxidation) and chronic PGC-1α upregulation (increasing mitochondrial density in muscle tissue). Human data is limited to case reports and unpublished observations, but protocols using 15mg MOTS-c three times weekly combined with resistance training show preliminary improvements in VO2max (12–18% increases) and reduced perceived exertion at submaximal workloads. These findings align with the peptide's role in mitochondrial biogenesis and metabolic flexibility.

MOTS-c alone produces measurable NAD+ elevation and mitochondrial function improvement — the USC studies used MOTS-c without exogenous NAD+ precursors and still demonstrated 39.6% NAD+ increase. However, combined protocols (MOTS-c + NMN or NR) show significantly greater effects: in vitro studies demonstrated 89% NAD+ increase with combination versus 41% with MOTS-c alone. The practical answer: MOTS-c works independently but performs better when substrate (NAD+ precursors) and enzymatic capacity (MOTS-c-induced NAMPT upregulation) are both optimized. For maximal metabolic restoration, evidence supports combination protocols over standalone use.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA